An example is the ongoing phase I/II DUCRO study (NCT03051906) analysing the use of the anti-PD-L1 monoclonal antibody, durvalumab, in combination with cetuximab and radiotherapy in locally advanced HNSCC in a cohort of patients with HPV-positive and HPV-negative HNSCCs. Here, CD274 is linked to head and neck squamous cell carcinoma.